Welcome to our dedicated page for Exagen news (Ticker: XGN), a resource for investors and traders seeking the latest updates and insights on Exagen stock.
Exagen Inc. develops and commercializes autoimmune diagnostic testing products under the AVISE brand. The company’s flagship AVISE CTD test is used by clinicians in evaluating complex rheumatic and autoimmune diseases, including lupus, rheumatoid arthritis and Sjögren’s disease, and its CLIA-certified, CAP-accredited laboratory specializes in rheumatic disease testing.
Recurring news for XGN includes quarterly and annual financial results, AVISE CTD test volume, average selling price, revenue, gross margin and cash updates. Company announcements also cover autoimmune biomarker research, additions to the AVISE testing portfolio, conference participation and corporate updates tied to Exagen’s diagnostics business.
Exagen (Nasdaq: XGN) reported second quarter 2026 revenue of $19.9 million, up 16% from $17.2 million in 2025, with record total revenue, test volume and a gross margin of 61.3%. AVISE CTD test volume grew 11% year over year and trailing twelve‑month average selling price rose 4% to $446 per test.
Net loss narrowed to $3.2 million from $4.4 million, while adjusted EBITDA improved to a loss of $0.1 million versus a $1.7 million loss a year earlier. Cash and cash equivalents were approximately $24.6 million at June 30, 2026. The company raised full‑year 2026 revenue guidance to $72–$75 million from $70–$73 million. Exagen also highlighted a published systematic review of over 3,100 patients across 14 medical centers supporting AVISE Lupus performance, showing AVISE CTD correctly identified about 25% of SLE patients missed by conventional markers.
Exagen (Nasdaq:XGN) announced that its management will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, MA on August 11, 2026. The company will host a Fireside Chat at 8:30 a.m. ET, with live and archived webcasts available on its investor relations website.
Exagen (Nasdaq: XGN) will release its financial results for the quarter ended June 30, 2026, before the market opens on Tuesday, August 4, 2026. Management will host a conference call at 8:30 a.m. ET (5:30 a.m. PT), with live webcast and replay access via the Exagen investor relations website.
Exagen (Nasdaq:XGN) announced a systematic review showing the AVISE Lupus algorithm delivers higher diagnostic accuracy than conventional serologic tests for systemic lupus erythematosus (SLE).
The analysis pooled 3,132 individuals from 14 academic centers (2011–2025), reported AUC up to 0.90, specificity above 98%, and uniquely identified about 25% of SLE patients missed by traditional markers.
Exagen (Nasdaq:XGN) reported record Q1 2026 revenue of $17.3 million, up 12% year over year, with gross margin of 59.0% and AVISE CTD test volume up 10%.
Trailing-twelve-month AVISE CTD ASP rose 6% to $444. Net loss was $4.0 million and adjusted EBITDA loss improved to $2.2 million. Cash and equivalents were about $22 million. Full-year 2026 revenue guidance remains $70–$73 million.
Exagen (Nasdaq: XGN) will release financial results for the quarter ended March 31, 2026, before the market opens on May 11, 2026.
John Aballi, President and CEO, and Jeff Black, CFO, will host a conference call and webcast at 8:30 a.m. ET (5:30 a.m. PT) that day. Webcast and replay will be available via the Exagen Investor Relations website; telephone replay available through May 25, 2026.
Exagen (NASDAQ: XGN) reported record 2025 results with $66.6M total revenue, a 20% increase, and AVISE CTD test volume growth of >11%. Trailing-twelve-month ASP rose to $441 (+7%). Company ended 2025 with $32.4M cash and raised capital via a $20M public offering and $25M credit facility.
Net loss was $19.95M for the year; 2026 revenue guidance is $70M–$73M.
Exagen (Nasdaq: XGN) announced management will participate in two investor conferences in March 2026: a virtual KeyBank Capital Markets Healthcare Forum on March 17, 2026 (investor meetings and a fireside chat at 3:00 p.m. ET) and the Roth Capital Conference in Laguna Niguel on March 23, 2026 (investor meetings).
Exagen (Nasdaq: XGN) will release fourth quarter and full year 2025 financial results before market open on March 10, 2026. Management will host a live conference call and webcast to review results.
Details: the call with CEO John Aballi and CFO Jeff Black is at 8:30 a.m. ET / 5:30 a.m. PT; a live webcast and a recorded replay will be available via the company investor relations website.
Exagen (Nasdaq: XGN) reported select preliminary unaudited results for the quarter and year ended December 31, 2025, consistent with prior guidance. Full-year revenue is projected at $66M–$67M, a 19%–20% increase versus 2024, and Q4 revenue is projected at $16M–$17M (up 17%–24%). The AVISE CTD test volume is 136,000–137,000 (TTM) with an ASP of $441–$445, an increase of at least $30 versus 2024. Year-end cash and cash equivalents were $32M, a $10M increase versus 2024. Results are preliminary and unaudited.